Page last updated: 2024-10-24

chloroquine and Disease Exacerbation

chloroquine has been researched along with Disease Exacerbation in 35 studies

Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.

Research Excerpts

ExcerptRelevanceReference
"Treatment Failure with chloroquine is one of the challenges that faced the dedicated efforts to eradicate malaria This study aims at investigating the impact of treatment failure with chloroquine on the progression of the disease-induced histo-pathogenic and immunogenic outcomes."7.96Progression of malaria induced pathogenicity during chloroquine therapy. ( Abd Majid, R; Abd Rachman-Isnadi, MF; Basir, R; Bello, RO; Chin, VK; Noor, SM; Sidek, HM; Zaid, OI, 2020)
"Chloroquine diphosphate has been used in the treatment of various rheumatic diseases, including rheumatoid arthritis."7.74Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration? ( Kochen, JA; Laurindo, IM; Maia, OO; Morita, C; Shinjo, SK; Takahashi, WY; Tizziani, VA, 2007)
"Chloroquine treatment increased whole lung and PASMC p62 protein levels consistent with inhibition of autophagy, and increased levels of BMPR-II protein."5.39Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. ( Dunmore, BJ; Long, L; Lu, J; Marciniak, SJ; Morrell, NW; Southwood, M; Yang, X, 2013)
"Progression of radiographic damage and association of radiographic damage and genetic predisposition were compared in two cohorts, one treated according to the delayed treatment strategy (initial treatment with analgesics), the other treated according to the early treatment strategy (treatment with disease modifying antirheumatic drugs (DMARDs) chloroquine or sulfasalazine)."5.11Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. ( Breedveld, FC; Hazes, JM; Huizinga, TW; Lard, LR; le Cessie, S; van Aken, J, 2004)
"Between 1993 and 1995, 109 patients diagnosed with probable or definite rheumatoid arthritis of recent onset were initially treated with analgesics; if they had persistent active disease, they were treated subsequently with the disease-modifying drugs chloroquine or salazopyrine (delayed treatment)."5.09Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. ( Breedveld, FC; Hazes, JM; Lard, LR; Speyer, I; vander Horst-Bruinsma, IE; Visser, H; Zwinderman, AH, 2001)
"Treatment Failure with chloroquine is one of the challenges that faced the dedicated efforts to eradicate malaria This study aims at investigating the impact of treatment failure with chloroquine on the progression of the disease-induced histo-pathogenic and immunogenic outcomes."3.96Progression of malaria induced pathogenicity during chloroquine therapy. ( Abd Majid, R; Abd Rachman-Isnadi, MF; Basir, R; Bello, RO; Chin, VK; Noor, SM; Sidek, HM; Zaid, OI, 2020)
"Chloroquine (CQ), a well-known anti-malarial drug, has long been used for the treatment of autoimmune diseases because of its profound immunomodulatory effects."3.80Early treatment with chloroquine inhibits the immune response against Plasmodium yoelii infection in mice. ( Cao, Y; Chen, G; Du, Y; Feng, Y; Pang, W; Qi, Z; Qin, X; Zhu, X, 2014)
" They were monitored for development of Plasmodium falciparum malaria, which was treated with chloroquine (CQ) + sulfadoxine-pyrimethamine (SP) and the children followed up for 28 days."3.76Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study. ( Egwang, TG; Kiyingi, HS; Nannyonga, M, 2010)
"Chloroquine diphosphate has been used in the treatment of various rheumatic diseases, including rheumatoid arthritis."3.74Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration? ( Kochen, JA; Laurindo, IM; Maia, OO; Morita, C; Shinjo, SK; Takahashi, WY; Tizziani, VA, 2007)
"Disease progression was observed in 18 patients (16."1.62Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital. ( Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W, 2021)
"Chloroquine-induced maculopathy may progress years after drug cessation and an apparent period of visual stability."1.46Delayed progression of bull's eye maculopathy. ( Jain, NG; Jain, S, 2017)
"Clinically, from the largest ovarian cancer data set (GSE 9899, n = 285) available in GEO, high levels of expression of both PTP4A3 and autophagy genes significantly predict poor prognosis of ovarian cancer patients."1.40A role of autophagy in PTP4A3-driven cancer progression. ( Al-Aidaroos, AQ; Gupta, A; Huang, YH; Lin, YB; McCrudden, CM; Murray, JT; Rozycka, E; Shen, HM; Tergaonkar, V; Thiery, JP; Yuen, HF; Zeng, Q; Zhang, SD, 2014)
"Chloroquine treatment increased whole lung and PASMC p62 protein levels consistent with inhibition of autophagy, and increased levels of BMPR-II protein."1.39Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. ( Dunmore, BJ; Long, L; Lu, J; Marciniak, SJ; Morrell, NW; Southwood, M; Yang, X, 2013)
" In patients in whom the daily dosage of hydroxychloroquine could be estimated (12 of 13), when using actual body weight, 8 were taking 6."1.37Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. ( Francis, PJ; Michaelides, M; Stover, NB; Weleber, RG, 2011)
"Twenty-two patients had some degree of renal failure; glomerular filtration rate (GFR) levels and albumin values were negatively associated to renal failure, while treatment with methylprednisolone decreased the probability of renal failure."1.35Prognostic factors in children with membranoproliferative glomerulonephritis type I. ( de Leon Bojorge, B; García-de la Puente, S; Orozco-Loza, IL; Zaltzman-Girshevich, S, 2008)

Research

Studies (35)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (5.71)18.2507
2000's9 (25.71)29.6817
2010's17 (48.57)24.3611
2020's7 (20.00)2.80

Authors

AuthorsStudies
Guidon, AC1
Amato, AA1
Xu, CY1
Lu, SD1
Ye, X1
Cao, MY1
Xu, GD1
Yu, Q1
Qian, JX1
Zeng, G1
Gegúndez-Fernández, JA1
Zarranz-Ventura, J1
Garay-Aramburu, G1
Muñoz-Negrete, FJ1
Mendicute Del Barrio, J1
Pablo-Júlvez, L1
García-Delpech, S1
López-Alemany, A1
Arnalich-Montiel, F1
Cordero-Coma, M1
Cárceles, JA1
Putman, M1
Chock, YPE1
Tam, H1
Kim, AHJ1
Sattui, SE1
Berenbaum, F1
Danila, MI1
Korsten, P1
Sanchez-Alvarez, C1
Sparks, JA1
Coates, LC1
Palmerlee, C1
Peirce, A1
Jayatilleke, A1
Johnson, SR1
Kilian, A1
Liew, J1
Prokop, LJ1
Murad, MH1
Grainger, R1
Wallace, ZS1
Duarte-García, A1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X10
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J4
Zhang, E1
Zhang, J3
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G3
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X2
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X5
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y4
Wu, X1
Lu, J3
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X3
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H1
Zhang, X4
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W3
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A2
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Zaid, OI1
Abd Majid, R1
Sidek, HM1
Noor, SM1
Abd Rachman-Isnadi, MF1
Bello, RO1
Chin, VK1
Basir, R1
Sirijatuphat, R1
Suputtamongkol, Y1
Angkasekwinai, N1
Horthongkham, N1
Chayakulkeeree, M1
Rattanaumpawan, P1
Koomanachai, P1
Assanasen, S1
Rongrungruang, Y1
Chierakul, N1
Ratanarat, R1
Jitmuang, A1
Wangchinda, W1
Kantakamalakul, W1
Jain, S1
Jain, NG1
Vidoni, C1
Ferraresi, A1
Seca, C1
Secomandi, E1
Isidoro, C1
Long, L1
Southwood, M1
Marciniak, SJ1
Dunmore, BJ1
Morrell, NW1
Kellner, S1
Weinitz, S1
Farmand, G1
Kellner, U1
Maes, H1
Martin, S1
Verfaillie, T1
Agostinis, P1
Huang, YH1
Al-Aidaroos, AQ1
Yuen, HF1
Zhang, SD1
Shen, HM1
Rozycka, E1
McCrudden, CM1
Tergaonkar, V1
Lin, YB1
Thiery, JP1
Murray, JT1
Zeng, Q1
Qin, X1
Feng, Y1
Zhu, X1
Du, Y1
Pang, W1
Qi, Z1
Cao, Y1
Ramadan, A1
Wheatcroft, MD1
Quan, A1
Singh, KK1
Lovren, F1
Dhingra, N1
Teoh, H1
Al-Omran, M1
Leong-Poi, H1
Verma, S1
Kong, J1
Whelan, KA1
Laczkó, D1
Dang, B1
Caro Monroig, A1
Soroush, A1
Falcone, J1
Amaravadi, RK1
Rustgi, AK1
Ginsberg, GG1
Falk, GW1
Nakagawa, H1
Lynch, JP1
Kasturi, N1
McCarthy, CG1
Wenceslau, CF1
Goulopoulou, S1
Baban, B1
Matsumoto, T1
Webb, RC1
Endo, S1
Nakata, K1
Ohuchida, K1
Takesue, S1
Nakayama, H1
Abe, T1
Koikawa, K1
Okumura, T1
Sada, M1
Horioka, K1
Zheng, B1
Mizuuchi, Y1
Iwamoto, C1
Murata, M1
Moriyama, T1
Miyasaka, Y1
Ohtsuka, T1
Mizumoto, K1
Oda, Y1
Hashizume, M1
Nakamura, M1
Michaelides, M1
Stover, NB1
Francis, PJ1
Weleber, RG1
Jenks, S1
Kiyingi, HS1
Egwang, TG1
Nannyonga, M1
Mir, A1
Tlougan, B1
O'Reilly, K1
Tzu, J1
Meehan, S1
Kamino, H1
Franks, AG2
Lotze, MT1
Buchser, WJ1
Liang, X1
Sirima, SB1
Konaté, A1
Tiono, AB1
Convelbo, N1
Cousens, S1
Pagnoni, F1
van Aken, J1
Lard, LR2
le Cessie, S1
Hazes, JM2
Breedveld, FC2
Huizinga, TW1
Shinjo, SK1
Maia, OO1
Tizziani, VA1
Morita, C1
Kochen, JA1
Takahashi, WY1
Laurindo, IM1
Brownell, I1
Soter, NA1
García-de la Puente, S1
Orozco-Loza, IL1
Zaltzman-Girshevich, S1
de Leon Bojorge, B1
Sisó, A1
Ramos-Casals, M1
Bové, A1
Brito-Zerón, P1
Soria, N1
Muñoz, S1
Testi, A1
Plaza, J1
Sentís, J1
Coca, A1
Kossard, S1
Lee, MS1
Wilkinson, B1
Vatti, R1
Sharma, OP1
Thoburn, CJ1
Miura, Y1
Sommer, M1
Hruban, R1
Qian, Z1
Baldwin, W1
Hess, AD1
Visser, H1
Speyer, I1
vander Horst-Bruinsma, IE1
Zwinderman, AH1
Sánchez-Guerrero, J1
Villegas, A1
Mendoza-Fuentes, A1
Romero-Díaz, J1
Moreno-Coutiño, G1
Cravioto, MC1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431]Phase 493 participants (Actual)Interventional2017-06-05Completed
The Effect of Tocilizumab (Anti-interleukin-6) Treatment on microRNA Expression and Adipokine Levels in Rheumatoid Arthritis Patients[NCT03149796]80 participants (Actual)Observational2011-03-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Serum Levels of Hydroxycloroquine

Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months

Interventionng/mL (Mean)
Inactive SLE With Standard Dose of HCQ991.6
Inactive SLE With Reduced Dose of HCQ569.0

Serum Levels of Thalidomide

Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months

Interventionng/mL (Mean)
SLE/Cutaneous Lupus With Thalidomide415.1

Reviews

5 reviews available for chloroquine and Disease Exacerbation

ArticleYear
COVID-19 and neuromuscular disorders.
    Neurology, 2020, 06-02, Volume: 94, Issue:22

    Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Delivery of Heal

2020
Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report.
    QJM : monthly journal of the Association of Physicians, 2020, 08-01, Volume: 113, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infectio

2020
Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19.
    Archivos de la Sociedad Espanola de Oftalmologia, 2020, Volume: 95, Issue:6

    Topics: Antimalarials; Asymptomatic Diseases; Betacoronavirus; Blood Safety; Chloroquine; Contact Lenses; Co

2020
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
    Arthritis & rheumatology (Hoboken, N.J.), 2021, Volume: 73, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Bias; C

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021

Trials

4 trials available for chloroquine and Disease Exacerbation

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis.
    Annals of the rheumatic diseases, 2004, Volume: 63, Issue:3

    Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Disease Progression; Epitopes

2004
Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases.
    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 1997, Volume: 14, Issue:1

    Topics: Adult; Aged; Alkaline Phosphatase; Antirheumatic Agents; Chloroquine; Diagnosis, Differential; Disea

1997
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.
    The American journal of medicine, 2001, Oct-15, Volume: 111, Issue:6

    Topics: Activities of Daily Living; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antir

2001

Other Studies

27 other studies available for chloroquine and Disease Exacerbation

ArticleYear
Progression of malaria induced pathogenicity during chloroquine therapy.
    Tropical biomedicine, 2020, Mar-01, Volume: 37, Issue:1

    Topics: Animals; Antimalarials; Chloroquine; Disease Progression; Malaria; Mice, Inbred ICR; Parasitemia; Pl

2020
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
    BMC infectious diseases, 2021, Apr-26, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treat

2021
Delayed progression of bull's eye maculopathy.
    BMJ case reports, 2017, Jun-08, Volume: 2017

    Topics: Aftercare; Aged; Antirheumatic Agents; Chloroquine; Disease Progression; Electroretinography; Female

2017
Methods for Monitoring Macroautophagy in Pancreatic Cancer Cells.
    Methods in molecular biology (Clifton, N.J.), 2019, Volume: 1882

    Topics: Animals; Autophagosomes; Autophagy; Autophagy-Related Proteins; Carcinogenesis; Cell Culture Techniq

2019
Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation.
    Circulation research, 2013, Apr-12, Volume: 112, Issue:8

    Topics: Animals; Autophagy; Bone Morphogenetic Protein Receptors, Type II; Cells, Cultured; Chloroquine; Dis

2013
Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation.
    The British journal of ophthalmology, 2014, Volume: 98, Issue:2

    Topics: Aged; Antirheumatic Agents; Chloroquine; Disease Progression; Electroretinography; Epiretinal Membra

2014
Dynamic interplay between autophagic flux and Akt during melanoma progression in vitro.
    Experimental dermatology, 2014, Volume: 23, Issue:2

    Topics: Autophagy; Cell Line, Tumor; Chloroquine; Disease Progression; Humans; In Vitro Techniques; Melanocy

2014
A role of autophagy in PTP4A3-driven cancer progression.
    Autophagy, 2014, Oct-01, Volume: 10, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Animals; Autophagy; Biocatalysis; Cell Cycle Proteins; Cell Me

2014
Early treatment with chloroquine inhibits the immune response against Plasmodium yoelii infection in mice.
    The Tohoku journal of experimental medicine, 2014, Volume: 234, Issue:4

    Topics: Animals; Antimalarials; Chloroquine; Dendritic Cells; Disease Models, Animal; Disease Progression; F

2014
Effects of long-term chloroquine administration on the natural history of aortic aneurysms in mice.
    Canadian journal of physiology and pharmacology, 2015, Volume: 93, Issue:8

    Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apolipoproteins E; Autophagy;

2015
Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress.
    Molecular carcinogenesis, 2016, Volume: 55, Issue:11

    Topics: Acids; Adenocarcinoma; Animals; Autophagy; Barrett Esophagus; Cell Line; Cell Survival; Chloroquine;

2016
Long-term continuation of chloroquine-induced retinal toxicity in rheumatoid arthritis despite drug cessation.
    Rheumatology (Oxford, England), 2016, Volume: 55, Issue:4

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Disease Progression; Humans; Male; Middle

2016
Chloroquine Suppresses the Development of Hypertension in Spontaneously Hypertensive Rats.
    American journal of hypertension, 2017, Volume: 30, Issue:2

    Topics: Animals; Blood Pressure; Blotting, Western; Chloroquine; Disease Models, Animal; Disease Progression

2017
Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mice.
    Gastroenterology, 2017, Volume: 152, Issue:6

    Topics: Animals; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chloroquine; Disease Progre

2017
Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2011, Volume: 129, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Disease Progression; Drug Therapy

2011
AACR highlights: promise for treating pancreatic cancer.
    Journal of the National Cancer Institute, 2011, May-18, Volume: 103, Issue:10

    Topics: Albumin-Bound Paclitaxel; Albumins; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combine

2011
Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study.
    The Pan African medical journal, 2010, Volume: 7

    Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Chloroquine; Disease Progression; Drug

2010
Morphea with discoid lupus erythematosus.
    Dermatology online journal, 2011, Oct-15, Volume: 17, Issue:10

    Topics: Antibodies, Bacterial; Arm; Atrophy; Borrelia burgdorferi; Chloroquine; Disease Progression; Doxycyc

2011
Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity.
    Autophagy, 2012, Volume: 8, Issue:8

    Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Chloroquine; Dendritic Cells; Disease P

2012
Early treatment of childhood fevers with pre-packaged antimalarial drugs in the home reduces severe malaria morbidity in Burkina Faso.
    Tropical medicine & international health : TM & IH, 2003, Volume: 8, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Aspirin; Burkina Faso; Child, Preschool; Chl

2003
Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?
    Clinical rheumatology, 2007, Volume: 26, Issue:8

    Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Disease Progression; Female;

2007
Familial linear scleroderma (en coup de sabre) responsive to antimalarials and narrowband ultraviolet B therapy.
    Dermatology online journal, 2007, Jan-27, Volume: 13, Issue:1

    Topics: Adult; Antimalarials; Chloroquine; Colchicine; Disease Progression; Drug Therapy, Combination; Femal

2007
Prognostic factors in children with membranoproliferative glomerulonephritis type I.
    Pediatric nephrology (Berlin, Germany), 2008, Volume: 23, Issue:6

    Topics: Adolescent; Alkylating Agents; Child; Child, Preschool; Chloroquine; Complement System Proteins; Cyc

2008
Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
    Lupus, 2008, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Aged; Antimalarials; Biopsy; Child; Chloroquine; Disease Progression; Female; Fol

2008
Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris.
    Journal of the American Academy of Dermatology, 1997, Volume: 36, Issue:1

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Antimalarials; Biopsy; Chloroquine; Dermato

1997
Autoimmune-mediated vasculopathy.
    Clinical immunology (Orlando, Fla.), 2001, Volume: 100, Issue:1

    Topics: Adoptive Transfer; Animals; Antigens, Differentiation, B-Lymphocyte; Arteriosclerosis; Autoimmune Di

2001
Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus.
    The American journal of medicine, 2001, Oct-15, Volume: 111, Issue:6

    Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Chloroquine; Cohort Studies; Disease Progression; Em

2001